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Abstract
Background: Fluconazole (FLC), a triazole antifungal drug, is widely used for the maintenance therapy of
cryptococcal meningoencephalitis, the most common opportunistic infection in AIDS patients. In this study, we
examined changes in the gene expression profile of the C. neoformans reference strain H99 (serotype A) following
FLC treatment in order to investigate the adaptive cellular responses to drug stress.
Results: Simultaneous analysis of over 6823 transcripts revealed that 476 genes were responsive to FLC. As
expected up-regulation of genes involved in ergosterol biosynthesis was observed, including the azole target gene
ERG11 and ERG13, ERG1, ERG7, ERG25, ERG2, ERG3 and ERG5. In addition, SRE1 which is a gene encoding a well-
known regulator of sterol homeostasis in C. neoformans was up-regulated. Several other genes such as those
involved in a variety of important cellular processes (i.e. lipid and fatty acid metabolism, cell wall maintenance,
stress and virulence) were found to be up-regulated in response to FLC treatment. Conversely, expression of AFR1,
the major transporter of azoles in C. neoformans, was not regulated by FLC.
Conclusions: Short-term exposure of C. neoformans to FLC resulted in a complex altered gene expression profile.
Some of the observed changes could represent specific adaptive responses to the antifungal agent in this
pathogenic yeast.
Background
Cryptococcus neoformans is a basidiomycetous fungal
pathogen that causes meningoencephalitis in predomi-
nantly immunocompromised hosts [1,2], that is the most
devastating manifestation of cryptococcal disease and is
fatal unless treated [3]. Cryptococcosis appears to be a sig-
nificant opportunistic infection in solid-organ transplant
recipients, with a prevalence rate ranging from 0.26% to
5% and overall mortality of 42% [4]. Notably, cryptococcal
meningitis was reported to occur in 46% of patients from
an Indian HIV-positive cohort [5]. Although the introduc-
tion of highly active antiretroviral therapy has led to a
decrease in the number of cryptococcal infections in AIDS
patients in most developed countries, this is not the case
in developing countries where the incidence of HIV/AIDS
and cryptococcal meningitis continue to rise [6]. As fluco-
nazole (FLC) became increasingly used due to the need for
life-long maintenance therapy in HIV/AIDS patients, FLC
resistance was hence detected at relatively high frequency
in C. neoformans clinical isolates from India, Africa and
Cambodia [7-9].
Increased FLC resistance in vitro was shown to be predic-
tive of treatment failures and infection relapses [10].
Recently, the mechanism underlying the heteroresistance to
FLC was elucidated [11], that is an adaptive mode of azole
resistance previously associated with FLC therapy failure
cases [12]. This mechanism is based on duplications of
multiple chromosomes in response to drug pressure [13].
Interestingly, Sionov et al. [13] observed that the number of
disomic chromosomes positively correlated with the dura-
tion of exposure to FLC, whereas the duplication of chro-
mosome 1 was closely associated with two genes, ERG11,
the target of FLC [14], and AFR1, the major transporter of
azoles in C. neoformans [11,15]. Such genomic plasticity
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C. neoformans strains of both serotypes, A (C. neoformans
var. grubii)a n dD( C. neoformans var. neoformans)[ 1 3 ] .
The recent sequencing of the C. neoformans genome
[16] has stimulated the development of C. neoformans-
specific microarrays that made possible to address
hypotheses about global responses to overcome stresses
during growth in the human host [17,18]. Regardless of
t h es o u r c e( i . e .h o s t - d e r i v e dor antifungal drugs), toxic
compounds exert constant selective pressure on the fun-
gus that responds by developing mechanisms necessary
for survival [19].
With the aim to identify genes required for adaptive
growth in the presence of sub-inhibitory concentrations
of FLC, we investigated here the transient response of
C. neoformans to FLC by analyzing differences in gene
expression prior and after FLC exposure of strain H99,
a reference strain of serotype A. Thus, genome-wide
transcriptional profiling of over 6823 C. neoformans
genes identified 476 genes with significant expression
changes. Apart from genes involved in ergosterol bio-
synthesis (e.g. ERG11), genes involved in other impor-
tant cellular functions, such as those encoding the sterol
homeostasis regulator Sre1 [20] or phospholipase B1
(Plb1) [21], were shown to be induced by FLC treat-
ment. In addition, AFR1 was not found FLC-responsive,
suggesting indirectly that this gene is responsible for
long-term FLC adaptation in C. neoformans.
Methods
Strain, growth conditions and RNA isolation
C. neoformans var. grubii serotype A strain (H99) was
obtained from David S. Perlin [22], kept as 20% glycerol
stock at -80°C and sub-cultured, as required, on YEPD (1%
yeast extract, 2% peptone, 2% glucose) agar plates at 30°C.
For RNA isolation independent overnight cultures were
diluted 1:100 in liquid YEPD and grown at 30°C or 37°C
with agitation for 3 h to reach a density of 3 × 10
7 CFU/ml.
At this point cultures were equally divided into two aliquots
to which either FLC at a concentration of 10 mg/l or dis-
tilled water was added, followed by incubation at 30°C or
37°C for 90 min. After this treatment, cultures were centri-
fuged at 4°C and 5500 × g and total RNA was extracted as
previously described [23].
Microarray design and preparation
C. neoformans H99 microarrays were designed following
the Agilent Array Design guidelines (Earray platform) by
first creating two separate sets of 60-base nucleotide
probes for each of 6967 open reading frame (ORF)
sequences as downloaded from the Broad Institute web-
site http://www.broadinstitute.org/annotation/genome/
cryptococcusneoformans/MultiHome.html. The probe
selection was performed using the GE Probe Design
Tool; probes were filtered following their base composi-
tion and distribution, cross-hybridization potential, and
melting temperature, to yield final duplicate probes
representing 6823 ORFs to cover 97.9% of the whole
C. neoformans H99 genome. C. neoformans custom
arrays were manufactured in the 8 × 15k format by Agi-
lent Technologies (Santa Clara, CA, USA). For quality
control and normalization purposes, 157 probes were
selected randomly and spotted 10 times throughout
each array. Standard controls (Agilent Technologies)
were also included.
cRNA synthesis, labeling and hybridization
RNA sample preparation was performed on three biolo-
gical triplicates of H99 cells grown at 30°C, as described
above. Prior to the labeling/amplification step, purity and
integrity of the RNA samples were determined using Agi-
lent RNA 6000 Nano LabChip kit on the Agilent 2100
bioanalyzer (Agilent Technologies). Agilent’s One-Color
Quick Amp Labeling kit (Agilent Technologies) was used
to generate fluorescently labeled cRNA probes according
to the manufacturer’s instructions. The method uses T7
RNA polymerase, which simultaneously amplifies target
material and incorporates cyanine 3-labeled CTP. The
labeled cRNAs were purified with the RNeasy Mini kit
(Qiagen, Hilden, Germany) and quantified using Nano-
Drop ND-1000 UV-VIS spectrophotometer. Aliquots
(600 ng) of Cy3-labeled cRNAs were fragmented and
hybridized for 17 h at 65°C to each array using the Gene
Expression Hybridization kit (Agilent Technologies) and
according to the manufacturer’s instructions.
Microarray imaging and data analysis
Slides were washed and processed according to the Agi-
lent 60-mer Oligo Microarray Processing protocol and
scanned on a Agilent microarray scanner G2565BA (Agi-
lent Technologies). Data were extracted from the images
with Feature Extraction (FE) software (Agilent Technolo-
gies). FE software flags outlier features, and detects and
removes spatial gradients and local backgrounds. Data
were normalized using a combined rank consistency fil-
tering with LOWESS intensity normalization. The gene
expression values obtained from FE software were
imported into GeneSpring 10.0.2 software (Agilent Tech-
nologies) for pre-processing and data analysis. For inter-
array comparisons, a linear scaling of the data was per-
formed using the 75th percentile signal value of all of
non-control probes on the microarray to normalize one-
colour signal values. Probe sets with a signal intensity
value below the 20th percentile were considered as
absent and discarded from subsequent analysis. The
expression of each gene was normalized by its median
expression across all samples. Genes were included in the
final data set if their expression changed by at least
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exposed (control sample) in at least two independent
experiments, together with a P-value cut-off of < 0.05 (by
one-way analysis of variance [ANOVA] corrected). Genes
listed in Table 1 were categorized by reported or putative
functions by the BROAD Institute database with NCBI
blastP http://www.ncbi.nlm.nih.gov/BLAST/ editing,
and also by the Uniprot http://www.uniprot.org/ and
Saccharomyces genome http://www.yeastgenome.org/cgi-
bin/blast-sgd.pl databases. As indicated in Table 1, each
S. cerevisiae gene name was assigned by blastP search
with the C. neoformans H99 gene sequence (e-value cut-
off: e
-6) according to Kim et al. [24]. Gene Ontology
(GO) term analysis was carried to help categorize a list of
genes into functional groups. The whole microarray data
have been deposited in National Center for Biotechnol-
ogy Information’s Gene Expression Omnibus [25] and
are accessible through GEO Series accession number
GSE24927.
Quantitative RT-PCR (qRT-PCR) validation of gene
expression
Expression of selected differentially regulated genes as
identified by the microarray analysis was quantitatively
assessed with qRT-PCR in an i-Cycler iQ system (Bio-
Rad Laboratories, Hercules, CA, USA). All primers and
probes (see Additional file 1) were designed with Beacon
Designer 2 (version 2.06) software (Premier Biosoft
International, Palo Alto, CA, USA) and synthesized by
MWG Biotech (Florence, Italy). qRT-PCRs were carried
out as previously described [23]. The annealing tempera-
ture used for all primers was 65°C. Each reaction was
run in triplicate on three separate occasions. For relative
quantification of target gene expression, ACT1 was used
as a normalizer gene [23]. Changes (n-fold) in gene
expression relative to that of the control were deter-
mined from mean ACT1-normalized expression levels.
Oxidative stress and cell wall inhibitor assays
Susceptibilities to hydrogen peroxide (H2O2)a n dc e l l
wall inhibitors were measured with exponentially grow-
ing cells in liquid YEPD at 30°C or 37°C pre-treated or
not with FLC (10 mg/l) for 90 min as described else-
where with modifications [26,27]. The cells were next
washed with sterile PBS and diluted to an OD650 of 1.0
in PBS. For the oxidative stress assays, aliquots of the
cell suspensions were transferred to Eppendorf tubes
where H2O2 (Sigma, Milan, Italy) was added to 20 mM
and incubated at 30°C or 37°C for 2 h. Viability was
determined after appropriate dilution of the samples
with PBS by plating 100 μl in triplicate on solid YEPD.
The CFU were counted after incubation for 72 h at 30°
C or 37°C. For the cell wall inhibitor assays, dilutions of
the cell suspensions were made in PBS and 5 μl of these
were grown on YEPD plates containing 0.5% Congo red
(Sigma, C-6767), 0.5, 1.0 and 1.5 mg ml
-1 calcofluor
white (Sigma, F-3543), 0.01%, 0.03% and 0.06% SDS
(Sigma) and 0.2, 0.5 and 1.0 mg ml
-1 caffeine (Sigma, C-
0750). Plates were incubated for 48 h at 30°C or 37°C
and photographed.
Results and Discussion
Experimental design and global gene expression results
The transcript profiles of C. neoformans H99 cells
e x p o s e dt o1 0m g / lo fF L C( 1 / 2×M I C )f o ro n ed o u -
bling time (90 min) at 30°C were compared with profiles
of untreated cells. A total of 476 genes were found
responsive to FLC treatment under the test conditions,
consisting of a single concentration and a single time
point as described elsewhere [28-30]. The threshold
value used in the present analysis was at least a twofold
difference of gene expression between the experimental
conditions, which is a value generally accepted in fungal
genome-wide expression profiling [31]. Given that
approximately 95% of the genes (6434/6823) spotted on
the microarrays gave validated data, the above men-
tioned number indicate that 7.4% of the total number of
genes in the C. neoformans H99 genome exhibited tran-
scriptional changes, with 231 genes being upregulated
and 245 downregulated upon FLC treatment.
In order to verify the changes in gene expression identi-
fied by our microarray analysis, we randomly selected 10
target genes (CNAG_00747, CNAG_01858, CNAG_02048,
CNAG_02226, CNAG_03007, CNAG_03204, CNAG_
04632, CNAG_03433, CNAG_05264, CNAG_05602)
including those regulated and not regulated by FLC for
validation of microarray data. A strong correlation (r =
0.94) was found between relative expression levels obtained
by microarray or qRT-PCR analysis (Figure 1). In addition,
qRT-PCR experiments performed with RNA extracted
from H99 cells FLC-treated at 37°C demonstrated that
expression of the target genes also including AFR1 was
comparable to that obtained when H99 cells were pre-trea-
ted with FLC at 30°C (Figure 2).
The genes listed in Table 1 were categorized in 10 main
groups by functional profiles as described in Methods.
The category with the largest number of genes was “trans-
port” with 31 genes, followed by categories that include
genes (n = 18) involved in carbohydrate metabolism or
protein processes (i.e. biosynthesis, modification, transport
and degradation). While up- or down-regulated genes
were distributed homogenously within almost all the func-
tion groups, some categories included more up-regulated
genes (ergosterol biosynthesis) or down-regulated genes
(TCA cycle). As it will be discussed below, the finding of a
large number of genes differentially regulated adds support
to the concept that azole activity is beyond the inhibition
of the lanosterol demethylase target encoded by ERG11
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BROAD ID
(CNAG_*****)
C. n. gene
name
S. c. gene
name
Description Fold
change
Ergosterol biosynthesis
04804 SRE1 Sterol regulatory element-binding protein 1 + 4.04
01737 ERG25 C-4 methyl sterol oxidase + 3.95
00854 ERG2 C-8 sterol isomerase + 3.47
02896 ERG13 Hydroxymethylglutaryl-CoA synthase + 3.03
06644 ERG5 C-22 sterol desaturase + 2.50
00040 ERG11 ERG11 Lanosterol 14 alpha-demethylase + 2.47
06829 ERG1 Squalene monooxygenase + 2.37
00519 ERG3 C-5 sterol desaturase + 2.21
01129 ERG7 Lanosterol synthase + 2.09
Transport
04632 FUR4 Uracil permease + 5.87
07448 DUR3 Urea transporter + 4.78
04758 MEP2/AMP2 Ammonium transporter + 3.78
06652 DAL5 Allantoate permease + 2.83
01742 AQY1 Water channel + 2.73
07902 CAN1 Amino acid transporter + 2.52
01960 YMR279C Efflux protein EncT + 2.47
06338 PDR15 ABC transporter PMR5 + 2.37
04898 ATR1 MFS transporter + 2.37
00284 YOR378W Efflux protein EncT + 2.36
00097 ITR1 ITR1 + 2.26
00895 ZRT1 Low-affinity zinc ion transporter + 2.20
04210 MPH2 Sugar transporter + 2.15
04617 OPT2 Small oligopeptide transporter + 2.11
05592 PMR1 Calcium-transporting ATPase + 2.06
01059 YBR241C Vacuolar membrane protein + 2.02
00904 AZR1 Aflatoxin efflux pump AFLT - 2.10
01769 AGC1 Mitochondrial inner membrane protein - 2.16
04142 FEN2 Tartrate transporter - 2.17
04567 TPO2 Drug transporter - 2.22
05387 HXT5 Galactose transporter - 2.28
02355 YEA4 UDP-N-acetylglucosamine transporter - 2.30
05994 FLR1 Multidrug transporter - 2.35
02733 STL1 Hexose transport-related protein - 2.46
03794 YBR287W Endoplasmic reticulum protein - 2.58
00815 SIT1 Siderochrome-iron (Ferrioxamine) uptake transporter - 2.92
01354 TNA1 Transporter - 3.39
02104 SFH5 SFH5 Phosphatidylinositol transfer protein SFH5 - 4.54
07695 UGA4 Gamma-aminobutyric acid transporter - 5.16
00749 YIL166C Transporter - 5.65
02083 ARN2 Siderochrome-iron transporter - 9.48
Cell wall maintenance
02217 CHS7 Chitin synthase 7 + 3.62
06336 BGL2 Glucan 1,3 beta-glucosidase protein + 2.61
03326 CHS2 Chitin synthase 2, CHS2 + 2.20
01239 CDA3 CDA2 Chitin deacetylase - 4.35
Capsule biosynthesis
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03644 CAS3 CAS3p + 12.16
01489 CAS9 YJL218W Putative O-acetyl transferase - 3.84
Lipid and fatty acid metabolism
06085 PLB1 PLB1 Phospholipase B + 2.18
06623 MIOX Myo-inositol oxygenase + 2.12
03128 ECM38 Lincomycin-condensing protein lmbA - 2.01
00424 PCT1 Choline-phosphate cytidylyltransferase - 2.02
05042 CAT2 Carnitine acetyltransferase - 2.10
02000 FOX2 Short-chain dehydrogenase - 2.95
00834 PSD2 Phosphatidylserine decarboxylase - 3.10
02968 PLC2 Phospholipase C-2 - 4.11
Cell stress
03400 GRE2 Oxidoreductase + 3.54
05256 CTA1 Catalase 2 + 2.81
02440 HSC82 Cation-transporting ATPase + 2.54
01750 HSP70 SSA1 Heat shock protein 70 + 2.48
06917 TSA3 PRX1 Thiol-specific antioxidant protein 3 + 2.09
03185 LOT6 Low temperature-responsive protein + 2.05
04622 SNG1 Response to drug-related protein - 2.17
00575 CTT1 Catalase - 2.21
01464 FHB1 YHB1 Flavo-haemoglobin - 2.32
Amino acid metabolism
02284 PDA1 Branched-chain alpha-keto acid dehydrogenase E1-alpha subunit + 2.42
04862 GLT1 Glutamate synthase (NADH) + 2.39
04017 MXR2 Protein-methionine-R-oxide reductase + 2.32
01231 CAR1 Arginase + 2.27
03828 ARO8 Aromatic amino acid aminotransferase I + 2.26
06540 ILV3 Dihydroxy-acid dehydratase + 2.18
00247 LYS9 Saccharopine dehydrogenase (NADP+, L-glutamate-forming) + 2.02
02270 MET2 Homoserine O-acetyltransferase - 2.11
01076 UGA1 4-aminobutyrate transaminase - 2.18
00237 LEU1 3-isopropylmalate dehydratase - 2.27
01264 LYS12 Isocitrate dehydrogenase - 2.31
00879 GDH2 Glutamate dehydrogenase - 2.33
04467 UGA2 Succinate-semialdehyde dehydrogenase (NAD(P)+) - 2.83
02851 GLY1 Threonine aldolase - 3.04
02049 PUT1 Proline dehydrogenase - 5.74
05602 PUT2 1-pyrroline-5-carboxylate dehydrogenase - 6.65
Carbohydrate metabolism
06374 MAE1 Malic enzyme + 6.04
02225 CELC EXG1 Cellulase + 3.99
02552 TKL1 Transketolase + 3.28
04025 TAL1 Transaldolase + 3.00
00696 AMS1 Alpha-mannosidase + 2.52
05913 MAL12 Alpha-glucosidase + 2.34
05113 ALD4 Aldehyde dehydrogenase (ALDDH) + 2.11
05264 YJL216C Alpha-amylase AmyA + 2.08
03946 GAL1 Galactokinase - 2.16
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07752 GLF UDP-galactopyranose mutase - 2.23
04659 PDC1 Pyruvate decarboxylase - 2.33
06924 SUC2 Beta-fructofuranosidase - 2.57
00269 SOR1 Sorbitol dehydrogenase - 2.62
00393 GLC3 GLC3 1,4-alpha-glucan-branching enzyme - 2.93
07745 MPD1 ADH3 Mannitol-1-phosphate dehydrogenase - 3.54
04217 PCK1 Phosphoenolpyruvate carboxykinase - 8.67
04621 GSY1 Glycogen (Starch) synthase - 11.00
04523 TDH3 Glyceraldehyde-3-phosphate dehydrogenase - 11.45
Protein biosynthesis, modification, transport, and degradation
02389 YPK1 AGC-group protein kinase + 3.04
02531 FUS3 Mitogen-activated protein kinase CPK1 + 2.91
03176 ERO1 Endoplasmic oxidoreductin 1 + 2.36
05932 CPR6 CPR6 Peptidyl-prolyl cis-trans isomerase D + 2.35
01861 NAS6 Proteolysis and peptidolysis-related protein + 2.35
04635 PEP4 Endopeptidase + 2.31
06872 YKL215C 5-oxoprolinase + 2.27
05005 ATG1 ATG1 Serine/threonine-protein kinase ATG1 + 2.20
00919 KEX1 Carboxypeptidase D + 2.13
04625 PRB1 Serine-type endopeptidase - 2.01
00130 RCK2 Serine/threonine-protein kinase - 2.12
04108 PKP1 Kinase - 2.17
02327 YFR006W Prolidase - 2.28
02418 DED81 Asparagine-tRNA ligase - 2.40
03563 DPS1 Aspartate-tRNA ligase - 2.50
04275 OMA1 Metalloendopeptidase - 2.50
02006 NTA1 Protein N-terminal asparagine amidohydrolase - 2.75
03949 PHO13 4-nitrophenylphosphatase - 3.32
TCA cycle
03596 KGD2 2-oxoglutarate metabolism-related protein - 2.02
03920 IDP1 Isocitrate dehydrogenase (NADP+) - 2.06
03674 KGD1 Oxoglutarate dehydrogenase (Succinyl-transferring) - 2.52
00747 LSC2 Succinate-CoA ligase (ADP-forming) - 2.70
07363 IDH2 Isocitrate dehydrogenase - 2.80
01137 ACO1 Aconitase - 2.99
07851 IDH1 Isocitrate dehydrogenase (NAD+), putative - 3.80
Glycerol metabolism
06132 RHR2 Glycerol-1-phosphatase + 2.31
02815 GUT2 Glycerol-3-phosphate dehydrogenase - 2.00
Nucleotide metabolism
05545 HNT2 Nucleoside-triphosphatase + 2.25
03078 NPP1 Type I phosphodiesterase/nucleotide pyrophosphatase family
protein
+ 2.08
06489 ADO1 Adenosine kinase - 2.08
00613 FCY1 Cytosine deaminase - 2.69
Thiamin metabolism
03592 THI20 Phosphomethylpyrimidine kinase - 2.51
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Alcohol metabolism
05258 SMG1 Glucose-methanol-choline (GMC) oxidoreductase + 6.67
05024 SPS19 L-xylulose reductase + 2.53
06168 GNO1 SFA1 GSNO reductase - 2.02
Carbon utilization
05144 CAN2 NCE103 Carbonic anhydrase 2 - 3.18
Cell cycle control
03385 PCL1 G1/s-specific cyclin pcl1 (Cyclin hcs26) + 2.37
02604 HOP1 Putative uncharacterized protein + 2.19
00995 MSC1 Meiotic recombination-related protein - 3.63
Chromatin and chromosome structures
02115 NHP6B Nonhistone protein 6 - 2.47
Transcription
01841 GLN3 Predicted protein + 5.72
02990 YOR052C Nucleus protein + 2.16
04594 UGA3 PRO1 protein - 2.01
05290 SPT3 Transcription cofactor - 2.01
06495 RNH70 Ribonuclease H - 2.06
05333 PUT3 Putative uncharacterized protein - 2.14
02338 GIS2 DNA-binding protein hexbp - 2.47
05479 ASG1 Putative uncharacterized protein - 3.57
Signal transduction
03316 RDI1 Rho GDP-dissociation inhibitor 1 + 2.07
00363 HHK5 SLN1 CnHHK5 protein - 2.44
01262 GPB1 STE4 G-protein beta subunit GPB1 - 2.55
Oxidoreduction
04652 YLR460C Enoyl reductase + 2.63
06035 ADH1 Alcohol dehydrogenase + 2.41
00605 ZTA1 Cytoplasm protein + 2.20
00038 SOR2 Alcohol dehydrogenase + 2.13
01954 YPR127W Aldo/keto reductase + 2.09
02958 FET5 Ferroxidase + 2.06
02935 YMR226C Oxidoreductase - 2.01
01558 XYL2 Zinc-binding dehydrogenase - 2.28
00876 FRE7 Ferric-chelate reductase - 2.49
03168 MET10 Sulfite reductase (NADPH) - 2.55
07862 YEL047C Fumarate reductase (NADH) - 2.58
03498 FRE2 Metalloreductase - 2.85
03874 AIF1 Oxidoreductase - 2.89
Other
00331 YMR210W Anon-23da protein + 3.43
04934 TAR1 Temperature associated repressor + 2.37
05678 ADY2 Membrane protein + 2.28
00818 AGE2 AGD15 + 2.23
04867 YJR054W Vacuole protein + 2.22
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gal resistance [33]. To further classify the genes regulated
by FLC exposure, we performed GO term analysis. As
expected, GO analysis of genes induced by FLC revealed a
significant enrichment of genes involved in sterol metabo-
lism, particularly ergosterol biosynthetic process (Table 2).
Enrichment of genes repressed by FLC was observed in
processes involving metabolism of amino acids and deriva-
tives (Table 2).
Effect of FLC on genes involved in ergosterol biosynthesis
and related pathways
Earlier efforts to profile the response of yeast cells
(S. cerevisiae or C. albicans) to the short-term exposure
to azole drugs implicated genes in the ergosterol biosyn-
thetic pathway as major players [28,29], thus indicating
that this pathway is the target of azoles and is respon-
sive to modulations in ergosterol levels. As shown in
T a b l e1 ,w ef o u n dt h a te i g h tERG genes (ERG1, ERG2,
ERG3, ERG5, ERG7, ERG11, ERG13 and ERG25)e x h i b -
ited increases in expression (2.09- to 3.95-fold) upon
FLC treatment. This was a predictable result from the
inhibition of Erg11 function by FLC, which is the rate-lim-
iting step of the ergosterol biosynthetic pathway. Indeed,
the idea of a compensatory response to re-establish the
plasma membrane ergosterol levels [30] may account for
the observed upregulation of either early (ERG13, ERG7
and ERG1) or late (ERG25, ERG2, ERG3 and ERG5) genes
Table 1 Changes in the gene expression of C. neoformans H99 cells exposed to FLC (Continued)
06574 APP1 Antiphagocytic protein 1 + 2.21
06482 AMD2 Amidase + 2.20
01252 TUM1 Thiosulfate sulfurtransferase - 2.05
03452 AFG1 AFG1 family mitochondrial ATPase - 2.16
05831 MMF1 Brt1 - 2.19
03991 YGR149W Integral to membrane protein - 2.39
02039 YPL264C Integral membrane protein - 2.46
02943 SLM1 Cytoplasm protein - 2.49
06668 AIM38 Mitochondrion protein - 2.61
00638 LSG1 GTPase - 2.89
01653 CIG Cytokine inducing-glycoprotein - 3.26
04314 YEF1 NAD+ kinase - 3.74
04690 FMP41 Mitochondrion protein - 5.52
Genes that were found to be differentially expressed were ordered by expression level and categorized, if available, into functional groups as described in
Materials and Methods. Results are presented as the mean fold-increase (symbol +) or -decrease (symbol -) of biological triplicates. Abbreviations: C. n., C.
neoformans; S. c., S. cerevisiae.
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Figure 1 Scatter plot of the results by microarray and
quantitative RT-PCR analyses for ten selected differentially
regulated genes in H99 cells FLC-treated (H99F) compared to
untreated control cells.
Figure 2 Results of qRT-PCR analysis performed with RNAs
extracted from H99 cells FLC-treated (H99F) at 30°C and 37°C.
The values, which are means of three separated experiments,
represent the increase in gene expression relative to untreated
control cells (set at 1.00). Error bars show standard deviations
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Page 8 of 13of the ergosterol pathway, in addition to upregulation of
ERG11 itself (Table 1, ergosterol biosynthesis).
ERG13 encodes the enzyme hydroxymethylglutaryl-CoA
synthase that catalyzes the production of hydroxymethyl-
glutaryl-CoA from acetyl-CoA and acetoacetyl-CoA, and
acts in the mevalonate biosynthesis, a precursor required
for the biosynthesis of ergosterol. Acetyl-CoA is converted
to carbon dioxide and water by enzymes (e.g. isocitrate
dehydrogenase) that function in the TCA cycle, a central
metabolic process in the mitochondria leading to produce,
after oxidative phosphorylation, chemical energy in the
form of ATP and NADH. Presumably, as a result of feed-
back control, we observed that several TCA cycle enzymes
were downregulated in response to FLC (Table 1, TCA
cycle), suggesting that C. neoformans may direct the cellu-
lar acetyl-CoA content to lipid (sterol) biosynthesis and
metabolism to counterbalance ergosterol alteration.
Our particular interest was the up-regulation (4.04-fold)
of SRE1, that belongs to a group of sterol regulatory ele-
ment-binding proteins (SREBPs), first characterized in
mammalian cells as regulator of lipid homeostasis [34].
While C. neoformans Sre1 regulates genes encoding ergos-
terol biosynthetic enzymes, SRE1 was shown to be
required for growth and survival in the presence of azoles
and also for virulence in a mouse model of cryptococcosis
[18,20,35]. In addition, C. neoformans Sre1 stimulates
ergosterol production in response to sterol depletion when
the oxygen-dependent ergosterol synthesis is limited by
hypoxia [36]. Consistently, C. neoformans mutants in the
SREBP pathway showed reduction in ergosterol levels,
increased sensitivity not only to low oxygen but also to
several chemical agents, including azole antifungals, CoCl2
and reactive oxygen species (ROS)-generating compounds.
Most importantly, these mutants showed reduced viru-
lence in mice [37].
Effect of FLC on genes involved in cell structure and
maintenance
Consequent to depletion of ergosterol and the concomi-
tant accumulation of 14-methylated sterols, several plau-
sible hypotheses on the mode of action of azoles were
suggested by Vanden Bossche [32] two decades ago
including alterations in membrane functions, synthesis
and activity of membrane-bound enzymes, mitochondrial
activities and uncoordinated activation of chitin synth-
esis. Transcript levels of several genes involving lipid and
fatty acid metabolism decreased in the current study
(Table 1), possibly in agreement with a remodelling of
the cell membrane in response to reduced ergosterol
levels. Conversely, expression of PLB1, that encodes Plb1,
a known virulence factor in C. neoformans, was increased
2.18-fold. Phospholipases cleave fatty acid moieties from
larger lipid molecules, releasing arachidonic acid for the
production of eicosanoids that are utilized by the patho-
genic yeasts C. neoformans and C. albicans to produce
immunomodulatory prostaglandins [38]. In addition, cell
wall-linked cryptococcal Plb1 contributes to cell wall
integrity and is a source of secreted enzyme [39].
Table 2 Gene Ontology (GO) term analysis for the C. neoformans FLC response
GO group GO subgroup P-value
Up-regulated genes
Oxidation reduction 5.26e
-10
Small molecule metabolic process 1.34e
-06
Alcohol metabolic process 4.74e
-07
Sterol metabolic process 4.41e
-07
Steroid metabolic process 7.81e
-07
Phytosteroid metabolic process 1.47e
-09
Steroid biosynthetic process 9.08e
-07
Ergosterol biosynthetic process 3.57e
-08
Transmembrane transport 0.00076
Down-regulated genes
Oxidation reduction 1.31e
-12
Small molecule metabolic process 2.50e
-11
Alcohol metabolic process 0.00037
Cellular ketone metabolic process 1.25e
-08
Cellular amino acid and derivative metabolic process 3.74e
-12
Organic acid metabolic process 1.63e
-08
Amine metabolic process 1.47e
-13
Gamma-aminobutyric acid metabolic process 0.00078
GO term assignment for C. neoformans H99 genes was based on homology to S. cerevisiae genes. P-value represents the probability that a particular GO term is
enriched in the microarray gene list. The P-value cut-off was < 0.05.
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genes responsible for cell wall integrity. Two chitin
synthase genes were found to be significantly up-regulated
(2.20-fold for CHS2 and 3.62-fold for CHS7), concomi-
tantly with down-regulated expression (4.35-fold) of the
chitin deacetylase CDA3 (homolog to S. cerevisiae CDA2)
(Table 1, cell wall maintenance). In C. albicans, activation
of chitin synthesis, which is mediated by the PKC-, Ca
2
+/calcineurin-, and HOG- cell wall signalling pathways,
appears to be an adaptive response to caspofungin treat-
ment. Hence, subculturing caspofungin-resistant cells in
the absence of caspofungin resulted in wild-type levels of
chitin content [40]. While this form of drug tolerance is
rationally accepted for a drug damaging the cell wall integ-
rity (caspofungin is known to reduce b-glucan synthesis),
it is also possible that exposure to azoles induces a salvage
mechanism involving the up-regulation of chitin synthesis.
Although known as a relatively minor cell wall compo-
nent, chitin is thought to contribute significantly to cryp-
tococcal wall strength and integrity [3]. Chitosan, the
enzymatically deacetytaled form of chitin, helps to main-
tain cell integrity and is necessary for maintaining normal
capsule width and retention of cell wall melanin [41]. Con-
sistently, up-regulation was observed for BGL2 (2.61-fold)
that encodes the glucantransferase (also termed glucosyl-
transferase) Bgl2, a major cell wall constituent described
in a wide range of yeast species.
Effect of FLC on genes involved in cell stress and
virulence
We found that FLC induced the expression of several
genes involved in oxidative-stress response (Table 1, cell
stress). One of these genes, GRE2, was induced 3.54-fold,
consistent with the previous observation that transcripts
from GRE2 and other stress-induced genes (YDR453C and
SOD2) were increased in S. cerevisiae exposed to azoles
[28]. Interestingly, loss of Gre2 is impairing tolerance to
ergosterol biosynthesis disrupting agents (i.e. clotrimazole
and ketoconazole), further supporting an association
between GRE2 and ergosterol metabolism [42]. YHB1 that
encodes a flavo-haemoglobin able to detoxify nitric oxide
in C. albicans and C. neoformans was down-regulated
2.32-fold in our study, which is opposed to its established
relevance in vivo [43]. A strong reduction in the expres-
sion of FHB1 (the C. neoformans ortholog of YHB1)w a s
also observed during growth of C. neoformans at 37°C
compared to 25°C, indicating that regulation of this gene
or its product at the posttranslational level may occur in
response to environmental changes [44]. In contrast,
CTA1 encoding catalase in S. cerevisiae was induced (2.81-
fold) by FLC exposure. Together with TSA3 (2.09-fold)
encoding thiol-specific antioxidant protein 3 (Table 1, cell
stress) and other responsive genes with oxidoreductase
a c t i v i t y( T a b l e1 ,oxidoreduction), these genes may
function in response to oxidative stress. Accordingly, the
stress-related gene encoding Ssa1 was also up-regulated
(2.48-fold). This C. neoformans protein (Hsp70 family
member) acts in vivo as transcriptional co-activator of lac-
case [45] and is important for the production of melanin,
which is a free-radical scavenger playing a protective role
in stress resistance [17].
The C. neoformans polysaccharide capsule is a complex
structure that is required for virulence [46,47]. Interest-
ingly, the capsule-associated gene CAS3 [48] was found
to be up-regulated (12.16-fold) upon exposure to the
drug (Table 1, capsule synthesis). This gene encodes a
protein belonging to a seven-member protein family that
includes Cap64. Treatment with FLC did not significantly
change expression of the essential capsule-producing
genes, CAP10, CAP59, CAP60 and CAP64.S i n c et h e
cryptococcal cell wall is needed for the localization or
attachment of known or putative virulence factors other
than capsule (i.e. melanin, Plb1 and Bgl2), it could be
hypothesized that FLC induces alterations in the cell wall
which in turns affects the expression of these factors. An
alternative hypothesis would be that FLC acts as a stress-
generating molecule and triggers enhanced expression of
virulence determinant(s) that enable to survive in hostile
environments.
Effect of FLC on genes involved in cellular transport
Several genes involved in small molecule transport and
vesicular transport were either up- or down-regulated in
response to FLC (Table 1, transport). These include DUR3
(plasma membrane transporter for urea, up-regulated
by 4.78-fold), MEP2/AMT2 (ammonium permease, up-
regulated by 3.78-fold) and AQY1 (aquaporin water chan-
nel, up-regulated by 2.73-fold), which all belong to the
group of C. neoformans genes regulated by osmotic stress
[49]. It is possible that defects in the plasma membrane
resulting from inhibition of ergosterol biosynthesis by FLC
affects transport of small molecules through the mem-
brane. Analysis of the H99 genome sequence [16] pre-
dicted 54 ATP-Binding Cassette (ABC) transporters and
159 major facilitator superfamily (MFS) transporters, sug-
gesting wide transport capabilities of this environmental
yeast [50]. However, we found only two S. cerevisiae trans-
porter homologues with significant increased expression.
One is PDR15 t h a ti sam e m b e ro ft h eA B Ct r a n s p o r t e r
subfamily exporting antifungals and other xenobiotics in
fungi [51]. The other gene is ATR1 that encodes a multi-
drug resistance transport protein belonging to the MFS
class of transporters. ATR1 expression was recently shown
to be upregulated by boron and several stress conditions
[52]. To date, Afr1 (encoded by AFR1;a l s ot e r m e d
CneAfr1) and CneMdr1 are the only two efflux pumps
associated with antifungal drug resistance in C. neofor-
mans [50]. Since Afr1 is the major efflux pump mediating
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Page 10 of 13azole resistance in C. neoformans [11,15], the absence of
altered AFR1 expression could be expected. Not surpris-
ingly, we noticed downregulated expression (2.35-fold) of
FLR1 (for fluconazole resistance) encoding a known MFS
multidrug transporter in yeast, that is able to confer resis-
tance to a wide range of dissimilar drugs and other chemi-
cals [53]. This may suggest that both AFR1 and FLR1 do
not participate to the short-term stress induced by FLC in
C. neoformans.
Effect of FLC on the susceptibility to cell wall inhibitors
It was demonstrated that compounds interfering with
normal cell wall formation (Congo red, calcofluor white,
SDS and caffeine) affect growth of C. neoformans strains
with altered cell wall integrity [27]. For instance, several
deletion strains for genes involved in the PKC1 signal
transduction pathway were found to be sensitive to SDS
and Congo red and to a lesser extent caffeine. To test
the hypothesis that FLC treatment might induce cell
wall stress, we analyzed H99 cells for susceptibility to
the cell wall perturbing agents, before and after the cells
were exposed for 90 min to FLC at sub-MIC concentra-
tion (10 mg/l) at 30°C. Phenotypes of H99 cells on cell
wall inhibitor plates are shown in Figure 3. The FLC
pre-treated H99 cells were slightly more resistant to all
four cell wall inhibitors as compared to untreated cells.
These findings are consistent with expression changes of
cell wall associated genes identified in our microarray
analysis. Particularly, since calcofluor white (which binds
to chitin) disrupts the cell wall and Congo red (which
binds to b-glucans) interferes with the cell wall biogen-
esis [27], the altered regulation of genes involved in the
chitin (CHS2 and CHS7)a n dg l u c a n( BGL2)s y n t h e s i s
may explain the phenotype of decreased susceptibility to
cell wall stress exhibited by FLC-exposed cells. Similar
results were obtained when H99 cells were pre-treated
with FLC at 37°C (see Additional file 2).
Effect of FLC on the susceptibility to H2O2
Because a number of FLC-responsive transcriptional
changes was found to affect genes involved in the oxida-
tive stress response (i.e. CTA1, GRE2), it seemed reason-
able to examine whether FLC at sub-inhibitory
concentrations could induce oxidative stress resistance in
vitro. For this purpose, exponentially growing H99 cells
that were treated with 10 mg/l FLC for 90 min were sub-
jected to an additional challenge with 20 mM H2O2.T h e
viable cells were next quantified on YEPD plates after
0.5, 1, 1.5 and 2 h of additional growth. As shown in
Figure 4, while untreated cells showed a high degree of
cell death, cells treated with FLC exhibited gained more
viability upon oxidative exposure at the endpoints of 1,
1.5 and 2 h. Similar results were obtained when H99 cells
were pre-treated with FLC at 37°C (see Additional file 3).
These findings indicate that FLC exposure is able to gen-
erate protection against oxidative stress in vitro, possibly
as a result of a transcriptional adaptive response.
Conclusions
Although exposure to azoles has been already investi-
gated in several other fungal species and the transcrip-
tional profile of differentially expressed genes was
obtained using a single FLC concentration and time
point, our study reveals several interesting findings.
First, we demonstrated that short-term exposure of C.
neoformans to FLC resulted in a complex altered gene
expression profile. These genes included not only genes
commonly responding to diverse environmental stresses,
such as oxidative and drug stresses, but also genes
encoding virulence factors (i.e. Plb1, Sre1 and capsule).
Second, we corroborated the potential of genome-wide
transcriptional analyses to envisage alternative therapeu-
tic strategies for cryptococcosis. Apart from ergosterol
and its biosynthesis, there are yet few other targets to be
1 mg/ml CFW          0.5% Congo Red 
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H99 
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Figure 3 Cell wall integrity assays with H99 C. neoformans cells
left untreated (H99) or exposed to FLC (H99F) at a sub-MIC
concentration of 10 mg/l for 90 min at 30°C. Cells were grown
at the same temperature for 48 h on YEPD supplemented with
calcofluor white (CFW), Congo red, sodium dodecyl sulphate (SDS)
and caffeine. Aliquots of cells were applied onto the agar surface
with 10-fold serial dilutions.
Figure 4 Survival of C. neoformans after oxidative treatment.
Exponentially growing cells were left untreated (H99) or exposed to
10 mg/l FLC (H99F) for 90 min at 30°C and then challenged with 20
mM H2O2 for 2 h. Aliquots were harvested at given time points and
cell viability performed as described in Methods. Plotted values are
means of three experiments
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Page 11 of 13exploited in anticryptococcal therapy. Therefore, eluci-
dation of molecular processes underlying the physiologi-
cal responses of cryptococcal cells to FLC could serve
not only to identify novel treatment approaches but also
to potentiate the inhibitory effects of existing azole
drugs. Our findings show that the phenomena described
can apply to the in vivo situation, i.e. during azole main-
tenance therapy in the host, but transcriptional analyses
using different growth conditions of H99 cells, mimick-
ing stress conditions encountered during a human
meningeal infection, may reveal new fields to pursue for
anticryptococcal therapy.
Additional material
Additional file 1: Table A1 Primers and fluorescent probes used in
qRT-PCR. Contains Table A1 showing the qRT-PCR primers and probes.
Additional file 2: Figure A1 Cell wall integrity assays with H99 C.
neoformans cells left untreated (H99) or exposed to FLC (H99F) at a
sub-MIC concentration of 10 mg/l for 90 min at 37°C. Cells were
grown at the same temperature for 48 h on YEPD supplemented with
calcofluor white (CFW), Congo red, sodium dodecyl sulphate (SDS) and
caffeine. Aliquots of cells were applied onto the agar surface with 10-fold
serial dilutions. Contains Figure A1 showing the results of cell wall
inhibitors susceptibility assays for H99 cells pre-treated with FLC at 37°C.
Additional file 3: Figure A2 Survival of C. neoformans after oxidative
treatment. Exponentially growing cells were left untreated (H99) or
exposed to 10 mg/l FLC (H99F) for 90 min at 37°C and then challenged
with 20 mM H2O2 for 2 h. Aliquots were harvested at given time points
and cell viability performed as described in Methods. Plotted values are
means of three experiments. Contains Figure A2 showing the results of
H2O2 susceptibility assays for H99 cells pre-treated with FLC at 37°C.
Acknowledgements
This work was supported by grants from the Istituto di Ricovero e Cura a
Carattere Scientifico (IRCCS) Lazzaro Spallanzani (Strategic Research Program
2006) to GF, from the Università Cattolica del S. Cuore (Fondi Ateneo Linea
D1-2009) to MS, and from the Swiss Research National Foundation
31003A_127378 to DS.
Author details
1Istituto di Microbiologia, Università Cattolica del Sacro Cuore, Largo F. Vito
1, 00168 Rome, Italy.
2Institute of Microbiology, University of Lausanne and
University Hospital Center, Lausanne, Rue du Bugnon 48, CH-1011 Lausanne,
Switzerland.
Authors’ contributions
MS, DS and BP designed the study; ARF and SF carried out the experimental
work; ARF, EDC and RT analysed the data; ARF and BP wrote the manuscript.
GF and DS corrected the manuscript. All the authors read and approved the
final manuscript.
Received: 22 December 2010 Accepted: 11 May 2011
Published: 11 May 2011
References
1. Perfect JR, Casadevall A: Cryptococcosis. Infect Dis Clin North Am 2002,
16:837-874.
2. Bicanic T, Harrison TS: Cryptococcal meningitis. Br Med Bull 2005,
72:99-118.
3. Doering TL: How sweet it is! Cell wall biogenesis and polysaccharide
capsule formation in Cryptococcus neoformans. Annu Rev Microbiol 2009,
63:223-247.
4. Silveira FP, Husain S: Fungal infections in solid organ transplantation. Med
Mycol 2007, 45:305-320.
5. Thakur R, Sarma S, Kushwaha S: Prevalence of HIV-associated cryptococcal
meningitis and utility of microbiological determinants for its diagnosis
in a tertiary care center. Indian J Pathol Microbiol 2008, 51:212-214.
6. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM:
Estimation of the current global burden of cryptococcal meningitis
among persons living with HIV/AIDS. AIDS 2009, 23:525-530.
7. Datta K, Jain N, Sethi S, Rattan A, Casadevall A, Banerjee U: Fluconazole
and itraconazole susceptibilities of clinical isolates of Cryptococcus
neoformans at a tertiary care centre in India; a need for care.
J Antimicrob Chemother 2003, 52:683-686.
8. Sar B, Monchy D, Vann M, Keo C, Sarthou JL, Buisson Y: Increasing in vitro
resistance to fluconazole in Cryptococcus neoformans Cambodian
isolates: April 2000 to March 2002. J Antimicrob Chemother 2004,
54:563-565.
9. Bii CC, Makimura K, Abe S, Taguchi H, Mugasia OM, Revathi G, Wamae NC,
Kamiya S: Antifungal drug susceptibility of Cryptococcus neoformans from
clinical sources in Nairobi, Kenya. Mycoses 2007, 50:25-30.
10. Perfect JR, Cox GM: Drug resistance in Cryptococcus neoformans. Drug
Resist Updat 1999, 2:259-269.
11. Sionov E, Chang YC, Garraffo HM, Kwon-Chung KJ: Heteroresistance to
fluconazole in Cryptococcus neoformans is intrinsic and associated with
virulence. Antimicrob Agents Chemother 2009, 53:2804-2815.
12. Mondon P, Petter R, Amalfitano G, Luzzati R, Concia E, Polacheck I, Kwon-
Chung KJ: Heteroresistance to fluconazole and voriconazole in
Cryptococcus neoformans. Antimicrob Agents Chemother 1999,
43:1856-1861.
13. Sionov E, Lee H, Chang YC, Kwon-Chung KJ: Cryptococcus neoformans
overcomes stress of azole drugs by formation of disomy in specific
multiple chromosomes. PLoS Pathog 2010, 6:e1000848.
14. Lupetti A, Danesi R, Campa M, Del Tacca M, Kelly S: Molecular basis of
resistance to azole antifungals. Trends Mol Med 2002, 8:76-81.
15. Posteraro B, Sanguinetti M, Sanglard D, La Sorda M, Boccia S, Romano L,
Morace G, Fadda G: Identification and characterization of a Cryptococcus
neoformans ATP binding cassette (ABC) transporter-encoding gene, CnAFR1,
involved in the resistance to fluconazole. Mol Microbiol 2003, 47:357-371.
16. Loftus BJ, Fung E, Roncaglia P, Rowley D, Amedeo P, Bruno D,
Vamathevan J, Miranda M, Anderson IJ, Fraser JA, Allen JE, Bosdet IE,
Brent MR, Chiu R, Doering TL, Donlin MJ, D’Souza CA, Fox DS, Grinberg V,
Fu J, Fukushima M, Haas BJ, Huang JC, Janbon G, Jones SJ, Koo HL,
Krzywinski MI, Kwon-Chung JK, Lengeler KB, Maiti R, Marra MA, Marra RE,
Mathewson CA, Mitchell TG, Pertea M, Riggs FR, Salzberg SL, Schein JE,
Shvartsbeyn A, Shin H, Shumway M, Specht CA, Suh BB, Tenney A,
Utterback TR, Wickes BL, Wortman JR, Wye NH, Kronstad JW, Lodge JK,
Heitman J, Davis RW, Fraser CM, Hyman RW: The genome of the
basidiomycetous yeast and human pathogen Cryptococcus neoformans.
Science 2005, 307:1321-1324.
17. Brown SM, Campbell LT, Lodge JK: Cryptococcus neoformans, a fungus
under stress. Curr Opin Microbiol 2007, 10:320-325.
18. Chun CD, Liu OW, Madhani HD: A link between virulence and
homeostatic responses to hypoxia during infection by the human fungal
pathogen Cryptococcus neoformans. PLoS Pathog 2007, 3:e22.
19. Coleman JJ, Mylonakis E: Efflux in fungi: la pièce de résistance. PLoS
Pathog 2009, 5:e1000486.
20. Chang YC, Bien CM, Lee H, Espenshade PJ, Kwon-Chung KJ: Sre1p, a
regulator of oxygen sensing and sterol homeostasis, is required for
virulence in Cryptococcus neoformans. Mol Microbiol 2007, 64:614-629.
21. Eisenman HC, Casadevall A, McClelland EE: New insights on the
pathogenesis of invasive Cryptococcus neoformans infection. Curr Infect
Dis Rep 2007, 9:457-464.
22. Soteropoulos P, Vaz T, Santangelo R, Paderu P, Huang DY, Tamás MJ,
Perlin DS: Molecular characterization of the plasma membrane H
+-ATPase, an antifungal target in Cryptococcus neoformans. Antimicrob
Agents Chemother 2000, 44:2349-2355.
23. Sanguinetti M, Posteraro B, La Sorda M, Torelli R, Fiori B, Santangelo R,
Delogu G, Fadda G: Role of AFR1, an ABC transporter-encoding gene, in
the in vivo response to fluconazole and virulence of Cryptococcus
neoformans. Infect Immun 2006, 74:1352-1359.
24. Kim MS, Ko YJ, Maeng S, Floyd A, Heitman J, Bahn YS: Comparative
transcriptome analysis of the CO2 sensing pathway via differential
Florio et al. BMC Microbiology 2011, 11:97
http://www.biomedcentral.com/1471-2180/11/97
Page 12 of 13expression of carbonic anhydrase in Cryptococcus neoformans. Genetics
2010, 185:1207-1219.
25. Barrett ER: Gene Expression Omnibus (GEO): Microarray data storage,
submission, retrieval, and analysis. Methods Enzymol 2006, 411:352-369.
26. Arana DM, Nombela C, Pla J: Fluconazole at subinhibitory concentrations
induces the oxidative- and nitrosative-responsive genes TRR1, GRE2 and
YHB1, and enhances the resistance of Candida albicans to phagocytes. J
Antimicrob Chemother 2010, 65:54-62.
27. Gerik KJ, Donlin MJ, Soto CE, Banks AM, Banks IR, Maligie MA,
Selitrennikoff CP, Lodge JK: Cell wall integrity is dependent on the PKC1
signal transduction pathway in Cryptococcus neoformans. Mol Microbiol
2005, 58:393-408.
28. Bammert GF, Fostel JM: Genome-wide expression patterns in
Saccharomyces cerevisiae: comparison of drug treatments and genetic
alterations affecting biosynthesis of ergosterol. Antimicrob Agents
Chemother 2000, 44:1255-1265.
29. De Backer MD, Ilyina T, Ma XJ, Vandoninck S, Luyten WH, Vanden
Bossche H: Genomic profiling of the response of Candida albicans to
itraconazole treatment using a DNA microarray. Antimicrob Agents
Chemother 2001, 45:1660-1670.
30. Gamarra S, Rocha EM, Zhang YQ, Park S, Rao R, Perlin DS: Mechanism of
the synergistic effect of amiodarone and fluconazole in Candida
albicans. Antimicrob Agents Chemother 2010, 54:1753-1761.
31. Karababa M, Coste AT, Rognon B, Bille J, Sanglard D: Comparison of gene
expression profiles of Candida albicans azole-resistant clinical isolates
and laboratory strains exposed to drugs inducing multidrug
transporters. Antimicrob Agents Chemother 2004, 48:3064-3079.
32. Vanden Bossche H: Biochemical targets for antifungal azole derivatives:
hypothesis on the mode of action. Curr Top Med Mycol 1985, 1:313-351.
33. Henry KW, Nickels JT, Edlind TD: Upregulation of ERG genes in Candida
species by azoles and other sterol biosynthesis inhibitors. Antimicrob
Agents Chemother 2000, 44:2693-2700.
34. Goldstein JL, Debose-Boyd RA, Brown MS: Protein sensors for membrane
sterols. Cell 2006, 124:35-46.
35. Bien CM, Chang YC, Nes WD, Kwon-Chung KJ, Espenshade PJ: Cryptococcus
neoformans Site-2 protease is required for virulence and survival in the
presence of azole drugs. Mol Microbiol 2009, 74:672-690.
36. Bien CM, Espenshade PJ: Sterol regulatory element binding proteins in
fungi: hypoxic transcription factors linked to pathogenesis. Eukaryot Cell
2010, 9:352-359.
37. Chang YC, Ingavale SS, Bien C, Espenshade P, Kwon-Chung KJ:
Conservation of the sterol regulatory element-binding protein pathway
and its pathobiological importance in Cryptococcus neoformans. Eukaryot
Cell 2009, 8:1770-1779.
38. Rhome R, Del Poeta M: Lipid signaling in pathogenic fungi. Annu Rev
Microbiol 2009, 63:119-131.
39. Siafakas AR, Sorrell TC, Wright LC, Wilson C, Larsen M, Boadle R,
Williamson PR, Djordjevic JT: Cell wall-linked cryptococcal phospholipase
B1 is a source of secreted enzyme and a determinant of cell wall
integrity. J Biol Chem 2007, 282:37508-37514.
40. Walker LA, Gow NA, Munro CA: Fungal echinocandin resistance. Fungal
Genet Biol 2010, 47:117-126.
41. Baker LG, Specht CA, Donlin MJ, Lodge JK: Chitosan, the deacetylated
form of chitin, is necessary for cell wall integrity in Cryptococcus
neoformans. Eukaryot Cell 2007, 6:855-867.
42. Warringer J, Blomberg A: Involvement of yeast YOL151W/GRE2 in
ergosterol metabolism. Yeast 2006, 23:389-398.
43. de Jesús-Berríos M, Liu L, Nussbaum JC, Cox GM, Stamler JS, Heitman J:
Enzymes that counteract nitrosative stress promote fungal virulence.
Curr Biol 2003, 13:1963-1968.
44. Kraus PR, Boily MJ, Giles SS, Stajich JE, Allen A, Cox GM, Dietrich FS,
Perfect JR, Heitman J: Identification of Cryptococcus neoformans
temperature-regulated genes with a genomic-DNA microarray. Eukaryot
Cell 2004, 3:1249-1260.
45. Zhang S, Hacham M, Panepinto J, Hu G, Shin S, Zhu X, Williamson PR: The
Hsp70 member, Ssa1, acts as a DNA-binding transcriptional co-activator
of laccase in Cryptococcus neoformans. Mol Microbiol 2006, 62:1090-1101.
46. Fromtling RA, Shadomy HJ, Jacobson ES: Decreased virulence in stable,
acapsular mutants of Cryptococcus neoformans. Mycopathologia 1982,
79:23-29.
47. Chang YC, Kwon-Chung KJ: Complementation of a capsule-deficient
mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol
1994, 14:4912-4919.
48. Moyrand F, Chang YC, Himmelreich U, Kwon-Chung KJ, Janbon G: Cas3p
belongs to a seven-member family of capsule structure designer
proteins. Eukaryot Cell 2004, 3:1513-1524.
49. Ko YJ, Yu YM, Kim GB, Lee GW, Maeng PJ, Kim S, Floyd A, Heitman J,
Bahn YS: Remodeling of global transcription patterns of Cryptococcus
neoformans genes mediated by the stress-activated HOG signaling
pathways. Eukaryot Cell 2009, 8:1197-1217.
50. Cannon RD, Lamping E, Holmes AR, Niimi K, Baret PV, Keniya MV, Tanabe K,
Niimi M, Goffeau A, Monk BC: Efflux-mediated antifungal drug resistance.
Clin Microbiol Rev 2009, 22:291-321.
51. Seret ML, Diffels JF, Goffeau A, Baret PV: Combined phylogeny and
neighborhood analysis of the evolution of the ABC transporters
conferring multiple drug resistance in hemiascomycete yeasts. BMC
Genomics 2009, 10:459.
52. Kaya A, Karakaya HC, Fomenko DE, Gladyshev VN, Koc A: Identification of a
novel system for boron transport: Atr1 is a main boron exporter in
yeast. Mol Cell Biol 2009, 29:3665-3674.
53. Sá-Correia I, dos Santos SC, Teixeira MC, Cabrito TR, Mira NP: Drug:H+
antiporters in chemical stress response in yeast. Trends Microbiol 2009,
17:22-31.
doi:10.1186/1471-2180-11-97
Cite this article as: Florio et al.: Genome-wide expression profiling of
the response to short-term exposure to fluconazole in Cryptococcus
neoformans serotype A. BMC Microbiology 2011 11:97.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Florio et al. BMC Microbiology 2011, 11:97
http://www.biomedcentral.com/1471-2180/11/97
Page 13 of 13